183 related articles for article (PubMed ID: 12947057)
1. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies.
Kaklamani VG; Hou N; Bian Y; Reich J; Offit K; Michel LS; Rubinstein WS; Rademaker A; Pasche B
J Clin Oncol; 2003 Sep; 21(17):3236-43. PubMed ID: 12947057
[TBL] [Abstract][Full Text] [Related]
2. Lack of an association between the TGFBR1*6A variant and colorectal cancer risk.
Skoglund J; Song B; Dalén J; Dedorson S; Edler D; Hjern F; Holm J; Lenander C; Lindforss U; Lundqvist N; Olivecrona H; Olsson L; Påhlman L; Rutegård J; Smedh K; Törnqvist A; Houlston RS; Lindblom A
Clin Cancer Res; 2007 Jun; 13(12):3748-52. PubMed ID: 17575241
[TBL] [Abstract][Full Text] [Related]
3. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.
Kaklamani VG; Baddi L; Liu J; Rosman D; Phukan S; Bradley C; Hegarty C; McDaniel B; Rademaker A; Oddoux C; Ostrer H; Michel LS; Huang H; Chen Y; Ahsan H; Offit K; Pasche B
Cancer Res; 2005 Apr; 65(8):3454-61. PubMed ID: 15833881
[TBL] [Abstract][Full Text] [Related]
4. TbetaR-I(6A) is a candidate tumor susceptibility allele.
Pasche B; Kolachana P; Nafa K; Satagopan J; Chen YG; Lo RS; Brener D; Yang D; Kirstein L; Oddoux C; Ostrer H; Vineis P; Varesco L; Jhanwar S; Luzzatto L; Massagué J; Offit K
Cancer Res; 1999 Nov; 59(22):5678-82. PubMed ID: 10582683
[TBL] [Abstract][Full Text] [Related]
5. The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer.
Colleran G; McInerney N; Rowan A; Barclay E; Jones AM; Curran C; Miller N; Kerin M; Tomlinson I; Sawyer E
Breast Cancer Res Treat; 2010 Jan; 119(2):437-42. PubMed ID: 19390964
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
Spillman MA; Schildkraut JM; Halabi S; Moorman P; Calingaert B; Bentley RC; Marks JR; Murphy S; Berchuck A
Gynecol Oncol; 2005 May; 97(2):543-9. PubMed ID: 15863158
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression.
Försti A; Li X; Wagner K; Tavelin B; Enquist K; Palmqvist R; Altieri A; Hallmans G; Hemminki K; Lenner P
Genes Chromosomes Cancer; 2010 Mar; 49(3):270-81. PubMed ID: 19998449
[TBL] [Abstract][Full Text] [Related]
8. Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer.
Chen T; Jackson CR; Link A; Markey MP; Colligan BM; Douglass LE; Pemberton JO; Deddens JA; Graff JR; Carter JH
Clin Cancer Res; 2006 Jan; 12(2):392-7. PubMed ID: 16428477
[TBL] [Abstract][Full Text] [Related]
9. TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
Song B; Margolin S; Skoglund J; Zhou X; Rantala J; Picelli S; Werelius B; Lindblom A
Br J Cancer; 2007 Oct; 97(8):1175-9. PubMed ID: 17848956
[TBL] [Abstract][Full Text] [Related]
10. Is TGFBR1*6A a susceptibility allele for nonsyndromic familial colorectal neoplasia?
Daley D; Morgan W; Lewis S; Willis J; Elston RC; Markowitz SD; Wiesner GL
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):892-4. PubMed ID: 17507611
[TBL] [Abstract][Full Text] [Related]
11. Role of TGF-beta in cancer and the potential for therapy and prevention.
Kaklamani VG; Pasche B
Expert Rev Anticancer Ther; 2004 Aug; 4(4):649-61. PubMed ID: 15270668
[TBL] [Abstract][Full Text] [Related]
12. Int7G24A variant of the TGFBR1 gene and cancer risk: a meta-analysis of three case-control studies.
Zhang HT
Lung Cancer; 2005 Sep; 49(3):419-20. PubMed ID: 15955593
[No Abstract] [Full Text] [Related]
13. The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer.
Krippl P; Langsenlehner U; Renner W; Yazdani-Biuki B; Köppel H; Leithner A; Wascher TC; Paulweber B; Samonigg H
Clin Cancer Res; 2004 May; 10(10):3518-20. PubMed ID: 15161710
[TBL] [Abstract][Full Text] [Related]
14. Association between TGFBR1*6A and cancer: is there any evidence?
Lai R
J Clin Oncol; 2004 Jul; 22(13):2754; author reply 2754-5. PubMed ID: 15226351
[No Abstract] [Full Text] [Related]
15. Somatic acquisition and signaling of TGFBR1*6A in cancer.
Pasche B; Knobloch TJ; Bian Y; Liu J; Phukan S; Rosman D; Kaklamani V; Baddi L; Siddiqui FS; Frankel W; Prior TW; Schuller DE; Agrawal A; Lang J; Dolan ME; Vokes EE; Lane WS; Huang CC; Caldes T; Di Cristofano A; Hampel H; Nilsson I; von Heijne G; Fodde R; Murty VV; de la Chapelle A; Weghorst CM
JAMA; 2005 Oct; 294(13):1634-46. PubMed ID: 16204663
[TBL] [Abstract][Full Text] [Related]
16. The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study.
Castillejo A; Mata-Balaguer T; Montenegro P; Ochoa E; Lázaro R; Martínez-Cantó A; Castillejo MI; Guarinos C; Barberá VM; Guillén-Ponce C; Carrato A; Soto JL
BMC Cancer; 2009 Jun; 9():193. PubMed ID: 19538729
[TBL] [Abstract][Full Text] [Related]
17. The association of polymorphisms on TGFBR1 and colorectal cancer risk: a meta-analysis.
Zhang X; Wu L; Sheng Y; Zhou W; Huang Z; Qu J; Gao G; Cai D; Zhang M
Mol Biol Rep; 2012 Mar; 39(3):2567-74. PubMed ID: 21858550
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759
[TBL] [Abstract][Full Text] [Related]
19. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
20. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies.
Pasche B; Kaklamani V; Hou N; Young T; Rademaker A; Peterlongo P; Ellis N; Offit K; Caldes T; Reiss M; Zheng T
J Clin Oncol; 2004 Feb; 22(4):756-8. PubMed ID: 14966109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
